Paradigm shift in neuroprotective drug development: Clinically tolerated NMDA receptor inhibition by memantine

Cell Death and Differentiation

Volumn 11, Issue 1, 2004, Pages 18-20

  Lipton, S A ^a,b,c   Chen, H S V ^a  

^a BURNHAM INSTITUTE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; PRIORITY JOURNAL; SIDE EFFECT;

DEMENTIA; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 1642474184     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401344     Document Type: Article

References (15)

1. Metzstein MM, Stanfield GM and Horvitz HR (1998) Trends Genet. 14: 410-416
2. Dimagl U, Iadecola C and Moskowitz MA (1999) Trends Neurosci. 22: 391-397
3. Olney JW (2003) Curr. Opin. Pharmacol. 3: 101-109
4. Bonfoco E et al. (1995) Proc. Natl. Acad. Sci. USA 92: 7162-7166
5. Masliah E (2000) Ann. NY Acad. Sci. 924: 68-75
6. Chen H-SV et al. (1992) J. Neurosci. 12: 4427-4436
7. Lipton SA (1993) Trends Neurosci. 16: 527-532
8. Lipton SA and Rosenberg PA (1994) N. Engl. J. Med. 330: 613-622
9. Chen H-SV and Lipton SA (1997) J. Physiol. (Lond.) 499: 27-46
10. Chen H-SV et al. (1998) Neuroscience 86: 1121-1132
11. Lei SZ et al. (1992) Neuron 8: 1087-1099
12. Lipton SA et al. (1993) Nature 364: 626-632
13. Choi Y-B et al. (2000) Nat. Neurosci. 3: 15-21
14. Le D and Lipton SA (2001) Drugs Aging 18: 717-724
15. Reisberg B et al. (2003) N. Engl. J. Med. 348: 1333-1341